Alan B. Sandler - 29 Sep 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Development Officer
Issuer ticker: RVMD
Reported as of: 29 Sep 2026
Net transaction value: -$1,275,294
SEC form: 4
Accepted by SEC: 01 Oct 2026, 18:00:04 UTC
Prior SEC filing: 18 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Alan B. Sandler

Key filing fact

Alan B. Sandler filed Form 4 for Revolution Medicines, Inc. (RVMD) on 01 Oct 2026.

Key facts

This page summarizes Alan B. Sandler's Form 4 filing for Revolution Medicines, Inc. (RVMD).
7 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Oct 2026, 18:00.

Change

Previous filing in this sequence was filed on 18 Sep 2026.
Current net transaction value: -$1,275,294.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835966 Primary reporting owner

Sandler Alan B.

Relationship: Chief Development Officer
Address: REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Alan B. Sandler
Signature date: 01 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +6,000
Change %: +11%
Price: $58.84^*
Shares after: 58,868
Date: 29 Sep 2026
Ownership: Direct
Footnotes: F1

RVMD transaction

Common Stock

Sale

Transaction value: $441,801
Shares: -2,200
Change %: -3.7%
Price: $200.82
Shares after: 56,668
Date: 29 Sep 2026
Ownership: Direct
Footnotes: F1, F2

RVMD transaction

Common Stock

Sale

Transaction value: $324,574
Shares: -1,609
Change %: -2.8%
Price: $201.72
Shares after: 55,059
Date: 29 Sep 2026
Ownership: Direct
Footnotes: F1, F3

RVMD transaction

Common Stock

Sale

Transaction value: $202,813
Shares: -1,000
Change %: -1.8%
Price: $202.81
Shares after: 54,059
Date: 29 Sep 2026
Ownership: Direct
Footnotes: F1, F4

RVMD transaction

Common Stock

Sale

Transaction value: $244,485
Shares: -1,199
Change %: -2.2%
Price: $203.91
Shares after: 52,860
Date: 29 Sep 2026
Ownership: Direct
Footnotes: F1, F5

RVMD transaction

Common Stock

Sale

Transaction value: $61,621
Shares: -301
Change %: -0.57%
Price: $204.72
Shares after: 52,559
Date: 29 Sep 2026
Ownership: Direct
Footnotes: F1, F6, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -6,000
Change %: -3.6%
Price: $0.000000^*
Shares after: 161,300
Date: 29 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 167,300
Exercise price: $58.84
Footnotes: F1, F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

Footnote F2

The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F4

The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F5

The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F6

The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F7

Includes 52,350 restricted stock units.

Footnote F8

Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.